


Amendments to the Claims

1. – 29. (canceled)

30. (new) A compound of formula (I) or a salt thereof:




wherein:

R¹ is ethyl, n-propyl, isopropyl, C₁₋₂fluoroalkyl, or -CH₂CH₂OH;

R² is hydrogen, methyl, ethyl, n-propyl, isopropyl, C₁₋₂fluoroalkyl, cyclopropyl or (cyclopropyl)methyl;

NHR³ has the sub-formula (nhr3):



wherein, in sub-formula (nhr3), the -NH- connection point of the NHR³ group to the bicyclic ring system of formula (I) is underlined, and wherein

R^{3a} is methyl or ethyl;

R^{3b} is hydrogen, methyl or ethyl,

R^{3c} is hydrogen, methyl or ethyl,

R^{3d} is hydrogen, methyl or ethyl, and

R^{3e} is hydrogen or methyl,

provided that:

(a) R^{3b} is methyl or ethyl; and (b) R^{3c} and R^{3d} are independently methyl or ethyl;

and provided that:

(c) when R^{3c} is ethyl and when R^{3d} is ethyl and when R^{3e} is methyl, then: R^{3a} is methyl and R^{3b} is hydrogen or methyl;

and wherein:


R⁵ is C₃-alkyl; C₃-gycycloalkyl optionally substituted by a C₁₋₂alkyl group; or -(CH₂)_n⁴-C₃-gycycloalkyl optionally substituted, in the -(CH₂)_n⁴- moiety or in the C₃-gycycloalkyl moiety, by a C₁₋₂alkyl group, wherein n⁴ is 1, 2 or 3;

or R⁵ is C₂₋₆alkyl substituted by one or two independent substituents R¹¹; wherein each substituent R¹¹, independently of any other R¹¹ substituent present, is: hydroxy; C₁₋₆alkoxy; phenyloxy; benzyloxy; -NR¹²R¹³; -NR¹⁵-C(O)R¹⁶; -NR¹⁵-C(O)-NH-R¹⁵; or -NR¹⁵-SO₂R¹⁶; and wherein any R¹¹ substituent which is OH, alkoxy or -NR¹²R¹³ is not substituted at the carbon atom, of any R⁵ substituted alkyl, which is bonded to the nitrogen of NHR⁵;

or R⁵ is -(CH₂)_n¹²-SO₂-NR¹²R¹³ or -(CH₂)_n¹²-SO₂R¹⁶; wherein n¹² is 2, 3 or 4;

or R⁵ is -(CH₂)_n¹³-Het wherein n¹³ is 0, 1, 2, 3 or 4 and Het is a 4-, 5-, 6- or 7-membered saturated or partly-saturated heterocyclic ring containing one or two ring-hetero-atoms independently selected from O, S, and N; wherein any ring-hetero-atoms present are not bound to the -(CH₂)_n¹³- moiety when n¹³ is 1 and are not bound to the nitrogen of NHR⁵ when n¹³ is 0; wherein any ring-nitrogens which are present and which are saturated are present as NR¹⁷; and wherein one or two of the carbon ring-atoms independently are optionally substituted by C₁₋₂alkyl;

or R⁵ has the sub-formula (x), (xa), (y), (y1), (z) or (za):



wherein in sub-formula (x), $n = 0, 1$ or 2 ; in sub-formula (y) and (y1), $m = 1$ or 2 ; and in sub-formula (z), $r = 0, 1$ or 2 ;

wherein sub-formula (y) and (y1), independently, are optionally substituted by oxo at a ring carbon adjacent the 6-membered aromatic ring;

and wherein, in sub-formula (xa) and (za):

R^{4a} is hydrogen; methyl, ethyl, n-propyl, isopropyl, C_{1-2} fluoroalkyl, cyclopropyl, $-CH_2OR^{4aa}$, $-CH(Me)OR^{4aa}$, or $-CH_2CH_2OR^{4aa}$, wherein R^{4aa} is hydrogen, methyl, or C_1 fluoroalkyl; and

R^{5a} is hydrogen; C_{1-8} alkyl; C_{1-3} fluoroalkyl; C_{3-8} cycloalkyl optionally substituted by a C_{1-2} alkyl group; or $-(CH_2)_n^{4a}-C_{3-8}$ cycloalkyl optionally substituted, in the $-(CH_2)_n^{4a}$ moiety or in the C_{3-8} cycloalkyl moiety, by a C_{1-2} alkyl group, wherein n^{4a} is 1 or 2 ;

or R^{5a} is C_{1-4} alkyl substituted by one substituent R^{11a} ; wherein R^{11a} is: hydroxy (OH); C_{1-6} alkoxy; C_{1-2} fluoroalkoxy; phenyloxy; (monofluoro- or difluoro-phenyl)oxy; (monomethyl- or dimethyl-phenyl)oxy; benzyloxy; $-NR^{12R13}$; $-NR^{15}.C(O)R^{16}$; $-NR^{15}.C(O).NH.R^{15}$; or $-NR^{15}.S(O)_2R^{16}$;

or R^{5a} is C_{2-4} alkyl substituted on different carbon atoms by two hydroxy substituents;

or R^{5a} is $-(CH_2)_n^{11a}.C(O)R^{16}$; $-(CH_2)_n^{11a}.C(O)NR^{12R13}$; $-CHR^{19a}.C(O)NR^{12R13}$; $-(CH_2)_n^{11a}.C(O)OR^{16}$; $-(CH_2)_n^{11a}.C(O)OH$; $-CHR^{19a}.C(O)OR^{16}$; $-CHR^{19a}.C(O)OH$; $-(CH_2)_n^{11a}.S(O)_2-NR^{12R13}$;

$-(CH_2)_n^{11a}-S(O)_2R^{16}$; or $-(CH_2)_n^{11a}-CN$; wherein n^{11a} is 0, 1, 2 or 3 wherein for each R^{5a} group n^{11a} is independent of the value of n^{11a} in other R^{5a} groups; and wherein R^{19a} is C_{1-2} alkyl;

or R^{5a} is $-(CH_2)_n^{13a}-Het^A$, wherein n^{13a} is 0, 1 or 2 and Het^A is a 4-, 5-, 6- or 7-membered saturated or unsaturated heterocyclic ring, other than $-NR^{12R^{13}}$, containing one or two ring-hetero-atoms independently selected from O, S, and N; wherein any ring-hetero-atoms present are not bound to the $-(CH_2)_n^{13a}$ moiety when n^{13a} is 0; wherein any ring-nitrogens which are present and which are saturated and which are not connecting nitrogens are present as NR^{17a} ; and wherein one or two of the carbon ring-atoms are independently optionally substituted by C_{1-2} alkyl;

or R^{5a} is phenyl, $-CH_2-Ph$, $-CHMe-Ph$, $-CHEt-Ph$, CMc_2Ph , or $-CH_2CH_2-Ph$, wherein the phenyl ring is optionally substituted with one or two substituents independently selected from the group consisting of a halogen atom; C_{1-4} alkyl; C_{1-2} fluoroalkyl; C_{1-4} alkoxy; C_{1-2} fluoroalkoxy; cyclopropyl; cyclopropyloxy; $-C(O)-C_{1-4}$ alkyl; $-C(O)OH$; $-C(O)-OC_{1-4}$ alkyl; C_{1-4} alkyl- $S(O)_2$ -; C_{1-4} alkyl- $S(O)_2-NR^{8a}$; $R^{7a}R^{8a}N-S(O)_2$ -; $R^{7a}R^{8a}N-C(O)$ -; $-NR^{8a}C(O)-C_{1-4}$ alkyl; $R^{7a}R^{8a}N$; OH; nitro ($-NO_2$); and cyano ($-CN$);

or R^{4a} and R^{5a} taken together are $-(CH_2)_p^{1-}$ or $-(CH_2)_p^{3-X^5}-(CH_2)_p^{4-}$, in which: X^5 is O or NR^{17a} ; $p^1 = 2, 3, 4, 5$ or 6 , and p^3 and p^4 independently are $1, 2$ or 3 provided that if p^3 is 3 then p^4 is 1 or 2 and if p^4 is 3 then p^3 is 1 or 2 ;

provided that at least one of R^{4a} and R^{5a} is not hydrogen;

and wherein, in sub-formula (x) and in sub-formula (xa):

A is $C-R^{6A}$, nitrogen or nitrogen-oxide,

B is $C-R^{6B}$, nitrogen or nitrogen-oxide,

D is $C-R^{6D}$, nitrogen or nitrogen-oxide,

E is $C-R^{6E}$, nitrogen or nitrogen-oxide,

F is $C-R^{6F}$, nitrogen or nitrogen-oxide,

wherein, R^{6A} , R^{6B} , R^{6D} , R^{6E} and R^{6F} independently are: hydrogen, a halogen atom; C_{1-6} alkyl; C_{1-4} fluoroalkyl; C_{3-6} cycloalkyl; C_{1-4} alkoxy; C_{1-2} fluoroalkoxy; C_{3-6} cycloalkyloxy; $-C(O)R^{16a}$; $-C(O)OR^{30}$; $-S(O)_2-R^{16a}$; $R^{16a}-S(O)_2-NR^{15a}$; $R^{7R^{8N}}-S(O)_2$ -; C_{1-2} alkyl- $C(O)-R^{15a}N-S(O)_2$ -; C_{1-4} alkyl- $S(O)$ -, $Ph-S(O)$ -, $R^{7R^{8N}}-CO$ -, $-NR^{15a}-C(O)R^{16a}$, $R^{7R^{8N}}$; nitro; OH; C_{1-4} alkoxymethyl; C_{1-4} alkoxyethyl; C_{1-2} alkyl- $S(O)_2-CH_2$ -; $R^{7R^{8N}}-S(O)_2-CH_2$ -;

C₁₋₂alkyl-S(O)₂-NR^{15a}CH₂-; -CH₂-OH; -CH₂CH₂-OH; -CH₂-NR^{7R8};
-CH₂-CH₂-NR^{7R8}; -CH₂-C(O)OR³⁰; -CH₂-C(O)-NR^{7R8};
-CH₂-NR^{15a}-C(O)-C₁₋₃alkyl; -(CH₂)_n¹⁴-Het¹ where n¹⁴ is 0 or 1; cyano; Ar^{5b}; or
phenyl, pyridinyl or pyrimidinyl wherein the phenyl, pyridinyl or pyrimidinyl
independently are optionally substituted by one or two substituents selected from the
group consisting of fluoro, chloro, C₁₋₂alkyl, C₁fluoroalkyl, C₁₋₂alkoxy and
C₁fluoroalkoxy;

and two adjacent groups are selected from the group consisting of R^{6A}, R^{6B},
R^{6D}, R^{6E} and R^{6F}, and are: -CH=CH-CH=CH₂-, -(CH₂)_n^{14a}- where n^{14a} is 3, 4
or 5, -O-(CMe₂)-O-, -O-(CH₂)_n^{14b}-O- where n^{14b} is 1 or 2; -CH=CH-NR^{15b};
-N=CH-NR^{15b};; -CH=N-NR^{15b};; -N=N-NR^{15b};; -CH=CH-O-; -N=CH-O-;
-CH=CH-S-; or -N=CH-S-; wherein R^{15b} is H or C₁₋₂alkyl;

provided that:

at least two of A, B, D, E and F are independently C-H, C-F, nitrogen, or
nitrogen-oxide;

and no more than two of A, B, D, E and F are independently nitrogen or
nitrogen-oxide,

and no more than one of A, B, D, E and F is nitrogen-oxide;

and wherein, in sub-formula (z) and in sub-formula (za):

G is O or S or NR⁹ wherein R⁹ is hydrogen, C₁₋₄alkyl, or C₁₋₂fluoroalkyl;

J is C-R^{6J}, C-[connection point to formula (I)], or nitrogen,

L is C-R^{6L}, C-[connection point to formula (I)], or nitrogen,

M is C-R^{6M}, C-[connection point to formula (I)], or nitrogen,

Q is C-R^{6Q}, C-[connection point to formula (I)], or nitrogen,

wherein, R^{6J}, R^{6L}, R^{6M} and R^{6Q} independently are: hydrogen, a halogen
atom; C₁₋₄alkyl; C₁₋₃fluoroalkyl; C₃₋₆cycloalkyl; C₁₋₄alkoxy; C₁₋₂fluoroalkoxy;
C₃₋₆cycloalkyloxy; OH (including any tautomer thereof); or phenyl optionally
substituted by one or two substituents independently selected from the group
consisting of fluoro, chloro, C₁₋₂alkyl, C₁fluoroalkyl, C₁₋₂alkoxy and
C₁fluoroalkoxy;

provided that:

at least two of J, L, M and Q are independently C-H, C-F, C-C₁₋₂alkyl,
C-[connection point to formula (I)], or nitrogen;

and no more than three of J, L, M and Q are nitrogen;

and wherein:

R⁷ and R⁸ are independently hydrogen; C₁₋₄alkyl; C₃₋₆cycloalkyl; or phenyl optionally substituted by one or two substituents independently selected from the group consisting of: fluoro, chloro, C₁₋₂alkyl, C₁fluoroalkyl, C₁₋₂alkoxy and C₁fluoroalkoxy;

or R⁷ and R⁸ together are -(CH₂)_n⁶- or -C(O)-(CH₂)_n⁷- or -C(O)-(CH₂)_n¹⁰-C(O)- or -(CH₂)_n⁸-X⁷-(CH₂)_n⁹- or -C(O)-X⁷-(CH₂)_n¹⁰ in which: n⁶ is 3, 4, 5 or 6, n⁷ is 2, 3, 4, or 5, n⁸ and n⁹ and n¹⁰ independently are 2 or 3, and X⁷ is O or NR¹⁴;

R^{7a} is hydrogen or C₁₋₄alkyl;

R^{8a} is hydrogen or methyl;

R¹² and R¹³, independent of any other R¹² or R¹³ independently are H; C₁₋₄alkyl; C₃₋₆cycloalkyl; or phenyl optionally substituted by one or two substituents independently selected from the group consisting of fluoro, chloro, C₁₋₂alkyl, C₁fluoroalkyl, C₁₋₂alkoxy and C₁fluoroalkoxy;

or R¹² and R¹³, independent of any other R¹² or R¹³, together are -(CH₂)_n^{6a}- or -C(O)-(CH₂)_n^{7a}- or -C(O)-(CH₂)_n^{10a}-C(O)- or -(CH₂)_n^{8a}-X¹²-(CH₂)_n^{9a}- or -C(O)-X¹²-(CH₂)_n^{10a}- in which: n^{6a} is 3, 4, 5 or 6, n^{7a} is 2, 3, 4, or 5, n^{8a} and n^{9a} and n^{10a} independently are 2 or 3 and X¹² is O or NR^{14a};

R¹⁴, R^{14a} and R^{17a}, independent of any other R¹⁴, R^{14a} or R^{17a}, independently are: hydrogen; C₁₋₄alkyl; C₁₋₂fluoroalkyl; cyclopropyl; -C(O)-C₁₋₄alkyl; -C(O)NR^{7a}R^{8a}; or -S(O)₂-C₁₋₄alkyl;

R¹⁵, independent of any other R¹⁵, is hydrogen; C₁₋₄alkyl; C₃₋₆cycloalkyl; or phenyl optionally substituted by one or two substituents independently selected from the group consisting of: a halogen atom, C₁₋₂alkyl, C₁fluoroalkyl, C₁₋₂alkoxy and C₁fluoroalkoxy;

R^{15a}, independent of any other R^{15a}, is hydrogen or C₁₋₄alkyl;

R¹⁶, independent of any other R¹⁶, is: C₁₋₄alkyl; C₃₋₆cycloalkyl; C₃₋₆cycloalkyl-CH₂-; or phenyl or benzyl, wherein the phenyl and benzyl are independently optionally substituted by one or two substituents independently

selected from the group consisting of fluoro, chloro, methyl, C₁fluoroalkyl, methoxy and C₁fluoroalkoxy;

R^{16a}, independent of any other R^{16a}, is: C₁₋₆alkyl; C₃₋₆cycloalkyl optionally substituted by one oxo, OH or C₁₋₂alkyl substituent; C₃₋₆cycloalkyl-CH₂; pyridinyl optionally substituted on a ring carbon atom by one of: a halogen atom, C₁₋₂alkyl, C₁fluoroalkyl, C₁₋₂alkoxy or C₁fluoroalkoxy; Ar^{5c}; phenyl optionally substituted by one or two substituents independently selected from the group consisting of: a halogen atom, C₁₋₂alkyl, C₁fluoroalkyl, C₁₋₂alkoxy and C₁fluoroalkoxy; benzyl optionally substituted on its ring by one or two substituents independently selected from the group consisting of: a halogen atom, C₁₋₂alkyl, C₁fluoroalkyl, C₁₋₂alkoxy, C₁fluoroalkoxy; or a 4-, 5-, 6- or 7-membered saturated heterocyclic ring connected at a ring-carbon and containing one or two ring-hetero-atoms independently selected from the group consisting of O, S, and N; wherein any ring-nitrogens which are present are present as NR²⁷ where R²⁷ is H, C₁₋₂alkyl or -C(O)Me; and wherein the ring is optionally substituted at carbon by one C₁₋₂alkyl or oxo substituent, provided that any oxo substituent is substituted at a ring-carbon atom bonded to a ring-nitrogen;


R¹⁷, independent of any other R¹⁷, is hydrogen; C₁₋₄alkyl; C₁₋₂fluoroalkyl; C₃₋₆cycloalkyl; -(CH₂)_p⁶-C(O)R¹⁶ wherein p⁶ is 0, 1, 2 or 3; -(CH₂)_p⁶-C(O)NR^{12R13}; -(CH₂)_p⁶-C(O)OR¹⁶; -(CH₂)_p⁶-C(O)OH; -SO₂R¹⁶; -C(O)-CH₂-NR^{12R13}; -C(O)-CH₂-NR^{15a}-C(O)-C₁₋₃alkyl; -C(O)-CH₂-O-C₁₋₃alkyl; or phenyl or benzyl wherein the phenyl or benzyl is optionally substituted on their ring by one or two substituents independently selected from the group consisting of: a halogen atom, C₁₋₂alkyl, C₁fluoroalkyl, C₁₋₂alkoxy and C₁fluoroalkoxy;

R³⁰, independent of any other R³⁰, is hydrogen, C₁₋₄alkyl or C₃₋₆cycloalkyl;

Ar^{5b} and Ar^{5c} independently are a 5-membered aromatic heterocyclic ring containing one O, S or NR^{15a}, the ring can optionally additionally contain one or two N atoms, and wherein the heterocyclic ring is optionally substituted on a ring carbon atom by a substituent selected from the group consisting of: halo, C₁₋₂alkyl, C₁fluoroalkyl, -CH₂OH, -CH₂-OC₁₋₂alkyl, OH, and -CH₂-NR^{28R29} wherein R²⁸ and R²⁹ independently are H or methyl; and


Het¹, independent of any other Het¹, is a 4-, 5-, 6- or 7-membered saturated heterocyclic ring connected at a ring-carbon and containing one or two ring-hetero-atoms independently selected from the group consisting of O, S, and N; wherein any ring-nitrogens which are present are present as NR³¹ where R³¹ is H, C₁₋₂alkyl or -C(O)Me; and wherein the ring is optionally substituted at carbon by one C₁₋₂alkyl or oxo substituent, provided that any oxo substituent is substituted at a ring-carbon atom bonded to a ring-nitrogen.

31. (new) A compound or salt as claimed in claim 30, wherein R¹ is ethyl or C₂fluoroalkyl.
32. (new) A compound or salt as claimed in claim 30, wherein R¹ is ethyl.
33. (new) A compound or salt as claimed in claim 30 wherein R² is hydrogen or methyl.
34. (new) A compound or salt as claimed in claim 30 wherein R^{3a} is methyl, R^{3b} is hydrogen or methyl, and R^{3c} is hydrogen.
35. (new) A compound or salt as claimed in claim 30 wherein R^{3b} is methyl or ethyl, R^{3c} and R^{3d} independently are-hydrogen or methyl, and R^{3e} is-hydrogen.
36. (new) A compound or salt as claimed in claim 35, wherein R³ is t-butyl.
37. (new) A compound or salt as claimed in claim 30 wherein R^{3c} and R^{3d} are independently methyl or ethyl, R^{3a} is methyl, and R^{3b} is hydrogen or methyl.
38. (new) A compound or salt as claimed in claim 37, wherein R³ is 1,2-dimethyl-propyl.
39. (new) A compound or salt as claimed in claim 30 wherein R^{3c} and R^{3d} are independently methyl or ethyl, R^{3b} is hydrogen and NHR³ has the sub-formula (nhr^{3a}):



wherein sub-formula (nhr3a) means that more than 50% of the compound or salt present has the stereochemistry shown at the carbon atom bearing the R^{3a} and R^{3b} groups.

40. (new) A compound or salt as claimed in claim 39 wherein NHR^3 has the sub-



41. (new) A compound or salt as claimed in claim 30 wherein R^5 is C_3 -galkyl; C_{5-6} -cycloalkyl; $(C_{5-6}$ -cycloalkyl)methyl-; $-(CH_2)_n-R^{11}$ wherein n is 2 or 3 or R^{11} is $-NR^{15}$ - SO_2R^{16} ; or R^5 has the sub-formula (x), (xa), (y), (y1), (z) or (za).

42. (new) A compound or salt as claimed in claim 41 wherein R^5 has the sub-formula (x), (xa), (y), (y1), (z) or (za).

43. (new) A compound or salt as claimed in claim 42 wherein R^5 has the sub-formula (x), (xa), (y), or (z).


44. (new) A compound or salt as claimed in claim 43 wherein R^5 has the sub-formula (x) or (xa).

45. (new) A compound or salt as claimed in claim 30 wherein $n = 1$, $m = 1$ and $r = 1$.

46. (new) A compound or salt as claimed in claim 44 wherein:

R^5 is sub-formula (x) which is $-(CH_2)_n-Ar^X$, or sub-formula (xa) which is $-(CR^{4a}R^{5a})-Ar^X$,

and Ar^X is sub-formula (x1), (x2), (x3), (x4), (x5), (x6), (x7), (x8), (x9), (x10), (x11), (x12), (x13), (x14), (x15) or (x16):



47. (new) A compound or salt as claimed in claim 46 wherein Ar^X has the sub-formula (x1).

48. (new) A compound or salt as claimed in claim 30 wherein, in sub-formula (x) and in sub-formula (xa), R^{6A} , R^{6B} , R^{6D} , R^{6E} and R^{6F} , independently of each other, are hydrogen, fluoro, chloro, bromo, iodo, methyl, ethyl, n-propyl, isopropyl, isobutyl, trifluoromethyl, $-CH_2OH$, methoxy, ethoxy, n-propoxy, isopropoxy,

C₁ fluoroalkoxy, nitro (-NO₂), OH, C₁₋₃alkylS(O)₂-, C₁₋₂alkylS(O)₂-NH-, -CONH₂, cyano (-CN), or C₁₋₂alkylS(O)₂-CH₂-.

49. (new) A compound or salt as claimed in claim 48 wherein R^{6A}, R^{6B}, R^{6D}, R^{6E} and R^{6F}, independently of each other, are: hydrogen, fluoro, chloro, bromo, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, -CH₂OH, methoxy, ethoxy, n-propoxy, difluoromethoxy, nitro (-NO₂), OH, MeS(O)₂-, Me-S(O)₂-NH- or Me-S(O)₂-CH₂-.

50. (new) A compound or salt as claimed in claim 30 wherein R⁵ is: benzyl, (monoalkyl-phenyl)methyl, [mono(fluoroalkyl)-phenyl]methyl, (monohalo-phenyl)methyl, (monoalkoxy-phenyl)methyl, [mono(fluoroalkoxy)-phenyl]methyl, [mono(N,N-dimethylamino)-phenyl]methyl, [mono(methyl-SO₂-NH-)-phenyl]methyl, [mono(methyl-SO₂-)-phenyl]methyl, (dialkyl-phenyl)methyl, (monoalkyl-monohalo-phenyl)methyl, [mono(fluoroalkyl)-monohalo-phenyl]methyl, (dihalo-phenyl)methyl, (dihalo-monoalkyl-phenyl)methyl, [dihalo-mono(hydroxymethyl)-phenyl]methyl, or (dialkoxy-phenyl)methyl.

51. (new) A compound or salt as claimed in claim 50 wherein R⁵ is:

(monoC₁₋₄alkyl-phenyl)methyl;
(monoC₁fluoroalkyl-phenyl)methyl;
(monoC₁₋₃alkoxy-phenyl)methyl;
[mono(C₁fluoroalkoxy)-phenyl]methyl;
(diC₁₋₂alkyl-phenyl)methyl;
(monoC₁₋₄alkyl-monohalo-phenyl)methyl;
(dihalo-phenyl)methyl;
(dihalo-monoC₁₋₂alkyl-phenyl)methyl; or
[dihalo-mono(hydroxymethyl)-phenyl]methyl.

52. (new) A compound or salt as claimed in claim 30 which is:

N-benzyl-4- {[(1R)-1,2-dimethylpropyl]amino}-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide,

4- {[(1R)-1,2-dimethylpropyl]amino}-1-ethyl-N-(4-fluorophenyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide,

4- {[(1R)-1,2-dimethylpropyl]amino}-1-ethyl-N-[4-(trifluoromethyl)benzyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide,

N-(2,3-dihydro-1H-inden-2-yl)-4- {[(1R)-1,2-dimethylpropyl]amino}-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide,

4- {[(1R)-1,2-dimethylpropyl]amino}-1-ethyl-N-[4-(methylsulfonyl)benzyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide,

N-[4-(difluoromethoxy)benzyl]-4- {[(1S)-1,2-dimethylpropyl]amino}-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide,

4- {[(1S)-1,2-dimethylpropyl]amino}-1-ethyl-N-[(2-methyl-1,3-thiazol-4-yl)methyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide,

N-[(5-chloropyridin-2-yl)methyl]-4- {[(1S)-1,2-dimethylpropyl]amino}-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide,

N-(2-chloro-6-fluorobenzyl)-4- {[(1S)-1,2-dimethylpropyl]amino}-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide,

4- {[(1S)-1,2-dimethylpropyl]amino}-1-ethyl-N- {1-[4-(methylsulfonyl)phenyl]ethyl}-1H-pyrazolo[3,4-b]pyridine-5-carboxamide,

4- {[(1S)-1,2-dimethylpropyl]amino}-1-ethyl-N-[(6-methoxypyridin-3-yl)methyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide,

4- {[(1S)-1,2-dimethylpropyl]amino}-1-ethyl-N- {3-[(methylamino)carbonyl]benzyl}-1H-pyrazolo[3,4-b]pyridine-5-carboxamide,

4- {[(1S)-1,2-dimethylpropyl]amino}-1-ethyl-N-[(1R)-1-phenylpropyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide,

4- {[(1S)-1,2-dimethylpropyl]amino}-N-(2,2-diphenylethyl)-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide,

N-[2-(dimethylamino)benzyl]-4- {[(1S)-1,2-dimethylpropyl]amino}-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide,

4- {[(1S)-1,2-dimethylpropyl]amino}-1-ethyl-N-(4-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide,

4- {[(1S)-1,2-dimethylpropyl]amino}-N-(diphenylmethyl)-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide,

4- {[(1S)-1,2-dimethylpropyl]amino }-1-ethyl-N- {4-
[(methylamino)carbonyl]benzyl}-1H-pyrazolo[3,4-b]pyridine-5-carboxamide,
methyl 4- ({[(1S)-1,2-dimethylpropyl]amino }-1-ethyl-1H-pyrazolo[3,4-
b]pyridin-5-yl)carbonyl]amino) methyl)benzoate,
4- {[(1S)-1,2-dimethylpropyl]amino }-1-ethyl-N-(4-methoxyphenyl)-1H-
pyrazolo[3,4-b]pyridine-5-carboxamide,
4- {[(1S)-1,2-dimethylpropyl]amino }-1-ethyl-N-(4-hydroxybenzyl)-1H-
pyrazolo[3,4-b]pyridine-5-carboxamide,
4- {[(1S)-1,2-dimethylpropyl]amino }-1-ethyl-N-[3-(trifluoromethyl)benzyl]-
1H-pyrazolo[3,4-b]pyridine-5-carboxamide,
4- {[(1S)-1,2-dimethylpropyl]amino }-1-ethyl-N-(4-methoxybenzyl)-1H-
pyrazolo[3,4-b]pyridine-5-carboxamide,
N-(3,4-difluorobenzyl)-4- {[(1S)-1,2-dimethylpropyl]amino }-1-ethyl-1H-
pyrazolo[3,4-b]pyridine-5-carboxamide,
N-(2,6-difluorobenzyl)-4- {[(1S)-1,2-dimethylpropyl]amino }-1-ethyl-1H-
pyrazolo[3,4-b]pyridine-5-carboxamide,
4- {[(1S)-1,2-dimethylpropyl]amino }-1-ethyl-N-[(1R)-1-phenylethyl]-1H-
pyrazolo[3,4-b]pyridine-5-carboxamide,
N-(2,5-difluorobenzyl)-4- {[(1S)-1,2-dimethylpropyl]amino }-1-ethyl-1H-
pyrazolo[3,4-b]pyridine-5-carboxamide,
4- {[(1S)-1,2-dimethylpropyl]amino }-1-ethyl-N-(3-fluorobenzyl)-1H-
pyrazolo[3,4-b]pyridine-5-carboxamide,
4- {[(1S)-1,2-dimethylpropyl]amino }-1-ethyl-N-[2-(trifluoromethyl)benzyl]-
1H-pyrazolo[3,4-b]pyridine-5-carboxamide,
N-(5-chloro-2,3-dihydro-1H-inden-2-yl)-4- {[(1S)-1,2-
dimethylpropyl]amino }-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide,
methyl 3- ({[(1S)-1,2-dimethylpropyl]amino }-1-ethyl-1H-pyrazolo[3,4-
b]pyridin-5-yl)carbonyl]amino) methyl)benzoate,
N-[2-(aminocarbonyl)benzyl]-4- {[(1S)-1,2-dimethylpropyl]amino }-1-ethyl-
1H-pyrazolo[3,4-b]pyridine-5-carboxamide,
4- {[(1S)-1,2-dimethylpropyl]amino }-1-ethyl-N- {4-
[(methylsulfonyl)amino]benzyl}-1H-pyrazolo[3,4-b]pyridine-5-carboxamide,

4- {[(1S)-1,2-dimethylpropyl]amino}-1-ethyl-N- {3-
[(methylsulfonyl)amino]benzyl}-1H-pyrazolo[3,4-b]pyridine-5-carboxamide,
4- {[(1S)-1,2-dimethylpropyl]amino}-1-ethyl-N-[4-(trifluoromethyl)benzyl]-
1H-pyrazolo[3,4-b]pyridine-5-carboxamide,
N-(2,3-dihydro-1H-inden-2-yl)-4- {[(1S)-1,2-dimethylpropyl]amino}-1-ethyl-
1H-pyrazolo[3,4-b]pyridine-5-carboxamide,
4- {[(1S)-1,2-dimethylpropyl]amino}-1-ethyl-N-[4-(methylsulfonyl)benzyl]-
1H-pyrazolo[3,4-b]pyridine-5-carboxamide,
N-benzyl-4- {[(1S)-1,2-dimethylpropyl]amino}-1-ethyl-1H-pyrazolo[3,4-
b]pyridine-5-carboxamide,
4- {[(1S)-1,2-dimethylpropyl]amino}-1-ethyl-N-(4-fluorophenyl)-1H-
pyrazolo[3,4-b]pyridine-5-carboxamide,
N-[2-(aminosulfonyl)ethyl]-4- {[(1S)-1,2-dimethylpropyl]amino}-1-ethyl-1H-
pyrazolo[3,4-b]pyridine-5-carboxamide,
4- {[(1S)-1,2-dimethylpropyl]amino}-1-ethyl-N-[(6-oxo-1,6-dihydropyridin-3-
yl)methyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide,
4- {[(1S)-1,2-dimethylpropyl]amino}-1-ethyl-N- {2-
[(methylsulfonyl)amino]ethyl}-1H-pyrazolo[3,4-b]pyridine-5-carboxamide,
4- {[(1S)-1,2-dimethylpropyl]amino}-1-ethyl-N-(tetrahydro-2H-pyran-4-yl)-
1H-pyrazolo[3,4-b]pyridine-5-carboxamide,
4- {[(1S)-1,2-dimethylpropyl]amino}-1-ethyl-N-[(1-methyl-1H-pyrazol-4-
yl)methyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide,
4- {[(1S)-1,2-dimethylpropyl]amino}-1-ethyl-N-[3-(methylsulfonyl)benzyl]-
1H-pyrazolo[3,4-b]pyridine-5-carboxamide,
4- {[(1S)-1,2-dimethylpropyl]amino}-1-ethyl-N-(pyridin-3-ylmethyl)-1H-
pyrazolo[3,4-b]pyridine-5-carboxamide,
N-[3-(aminocarbonyl)benzyl]-4- {[(1S)-1,2-dimethylpropyl]amino}-1-ethyl-
1H-pyrazolo[3,4-b]pyridine-5-carboxamide,
4- {[(1S)-1,2-dimethylpropyl]amino}-1-ethyl-N-(tetrahydrofuran-2-ylmethyl)-
1H-pyrazolo[3,4-b]pyridine-5-carboxamide,
N- {4-[(dimethylamino)sulfonyl]benzyl}-4- {[(1S)-1,2-dimethylpropyl]amino}-
1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide,

4- {[(1S)-1,2-dimethylpropyl]amino}-1-ethyl-N-(2-ethylbutyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide,

4-(tert-butylamino)-1-ethyl-N-benzyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide,

4-(tert-butylamino)-1-ethyl-N-(4-fluorophenyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide,

4-(tert-butylamino)-1-ethyl-N-[4-(trifluoromethyl)benzyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide,

4-(tert-butylamino)-N-(2,3-dihydro-1H-inden-2-yl)-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide, or

4-(tert-butylamino)-1-ethyl-N-[4-(methylsulfonyl)benzyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide.

53. (new) A pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof as defined in claim 30 and one or more pharmaceutically acceptable carriers and/or excipients.

54. (new) A method of treatment and/or prophylaxis of an inflammatory and/or allergic disease in a human in need thereof which method comprises administering to the human a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof as defined in claim 30.

55. (new) The method of claim 54 wherein the disease is chronic obstructive pulmonary disease or asthma.